Table 3 Summary of clinico-pathological variables in TP53 mutant breast cancer patients age ≤ 40 years, after excluding BRCA carriers (n = 407)
From: Prevalence of germline TP53 mutation among early onset middle eastern breast cancer patients
Clinico-pathological variables | TP53 carriers (n = 7) | TP53 non-carriers (n = 400) | p value |
|---|---|---|---|
n (%) | n (%) | ||
Age at diagnosis, years | |||
Mean ± SD | 32.0 ± 6.0 | 34.9 ± 4.6 | 0.2410 |
Median (range) | 32 (22 – 39) | 36 (13 – 40) | 0.1380 |
≤30 | 3 (4.7) | 61 (95.3) | 0.0813 |
31 – 40 | 4 (1.2) | 339 (98.8) | |
Family history of breast cancer | |||
Yes | 0 (0.0) | 42 (100.0) | 1.0000 |
No | 7 (1.9) | 358 (98.1) | |
Family history of any cancer | |||
Yes | 1 (1.4) | 71 (98.6) | 1.0000 |
No | 6 (1.8) | 329 (98.2) | |
Personal history of other cancer | |||
Yes | 0 (0.0) | 4 (100.0) | 1.0000 |
No | 7 (1.7) | 396 (98.3) | |
Bilateral breast cancer | |||
Yes | 2 (66.7) | 1 (33.3) | 0.0008* |
No | 5 (1.2) | 399 (98.8) | |
Tumor size | |||
≤2 cm | 1 (0.8) | 120 (99.2) | 0.4441 |
>2 cm | 6 (2.2) | 264 (97.8) | |
Lymph node status | |||
Negative | 3 (2.2) | 134 (97.8) | 0.6996 |
Positive | 4 (1.6) | 250 (98.4) | |
Distant metastasis | |||
Absent | 4 (1.1) | 355 (98.9) | 0.0139* |
Present | 3 (9.4) | 29 (90.6) | |
Stage | |||
I | 0 (0.0) | 63 (100.0) | 0.0481* |
II | 2 (1.4) | 144 (98.6) | |
III | 2 (1.3) | 148 (98.7) | |
IV | 3 (9.4) | 29 (90.6) | |
Histologic Grade | |||
Well differentiated | 0 (0.0) | 28 (100.0) | 0.3018 |
Moderately differentiated | 2 (1.1) | 174 (98.9) | |
Poorly differentiated | 5 (2.8) | 173 (97.2) | |
Estrogen receptor status | |||
Positive | 4 (1.6) | 246 (98.4) | 1.0000 |
Negative | 3 (1.9) | 154 (98.1) | |
Progesterone receptor status | |||
Positive | 3 (1.4) | 217 (98.6) | 0.7078 |
Negative | 4 (2.1) | 183 (97.9) | |
Her-2 neu status | |||
Positive | 3 (1.7) | 169 (98.3) | 1.0000 |
Negative | 4 (1.7) | 231 (98.3) | |
Molecular Subtype | |||
Luminal | 4 (1.4) | 274 (98.6) | 0.7464 |
Her-2 positive | 2 (2.9) | 68 (97.1) | |
TNBC | 1 (1.7) | 58 (98.3) | |
Overall survival (5-years) | 33.3 | 82.5 | 0.0003* |